[go: up one dir, main page]

GB1010509A - Improvements in or relating to newcastle disease virus vaccines - Google Patents

Improvements in or relating to newcastle disease virus vaccines

Info

Publication number
GB1010509A
GB1010509A GB7111/62A GB711162A GB1010509A GB 1010509 A GB1010509 A GB 1010509A GB 7111/62 A GB7111/62 A GB 7111/62A GB 711162 A GB711162 A GB 711162A GB 1010509 A GB1010509 A GB 1010509A
Authority
GB
United Kingdom
Prior art keywords
tissue culture
virus
newcastle disease
disease virus
avian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB7111/62A
Inventor
Nicholas Michael Larin
John Norman Pilfold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Pfizer Ltd Great Britain
Original Assignee
PFIZER Ltd
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd
Priority to GB7111/62A priority Critical patent/GB1010509A/en
Priority to DEP31192A priority patent/DE1179670B/en
Priority to BR147168/63A priority patent/BR6347168D0/en
Publication of GB1010509A publication Critical patent/GB1010509A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Live Newcastle Disease virus vaccine is prepared by inoculating a non-avian tissue culture with a seed of an attenuated strain of Newcastle Disease virus, taken from avian tissue, cultivating the virus in the non-avian tissue culture and then harvesting the virus-containing fluid from the tissue culture before the appearance of a cytopathic effect in the tissue culture cells. The non-avian tissue culture used is preferably that obtained from the kidneys of monkeys, calves or pigs. The virus-containing fluid obtained may be mixed with a minor proportion by volume of bovine serum and/or skimmed milk and after adjusting, if necessary, the pH of the mixture so formed to approximately 7, protamine or clupeine sulphate is added and the resultant precipitate is harvested. This precipitate can be reconstituted to the desired concentration by admixture with a suitable diluent, e.g. physiologically-buffered saline solution.
GB7111/62A 1962-02-23 1962-02-23 Improvements in or relating to newcastle disease virus vaccines Expired GB1010509A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB7111/62A GB1010509A (en) 1962-02-23 1962-02-23 Improvements in or relating to newcastle disease virus vaccines
DEP31192A DE1179670B (en) 1962-02-23 1963-02-22 Process for making vaccine against Newcastle disease
BR147168/63A BR6347168D0 (en) 1962-02-23 1963-02-22 VACCINE PREPARATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7111/62A GB1010509A (en) 1962-02-23 1962-02-23 Improvements in or relating to newcastle disease virus vaccines

Publications (1)

Publication Number Publication Date
GB1010509A true GB1010509A (en) 1965-11-17

Family

ID=9826810

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7111/62A Expired GB1010509A (en) 1962-02-23 1962-02-23 Improvements in or relating to newcastle disease virus vaccines

Country Status (3)

Country Link
BR (1) BR6347168D0 (en)
DE (1) DE1179670B (en)
GB (1) GB1010509A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2058645A1 (en) * 1969-11-29 1971-06-09 Takeda Chemical Industries Ltd Process for the preparation of live attenuated Newcastle Disease Virus vaccine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU826584A1 (en) * 1979-10-29 1982-11-07 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Vaccine against newcastle fowl disease, process for preparing the same and method for prophylaxis of newcastle fowl diease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2058645A1 (en) * 1969-11-29 1971-06-09 Takeda Chemical Industries Ltd Process for the preparation of live attenuated Newcastle Disease Virus vaccine
FR2073436A1 (en) * 1969-11-29 1971-10-01 Takeda Chemical Industries Ltd

Also Published As

Publication number Publication date
DE1179670B (en) 1964-10-15
BR6347168D0 (en) 1973-08-02

Similar Documents

Publication Publication Date Title
Rosanoff Hemagglutination and hemadsorption of measles virus
Breitenbach et al. Pituitary prolactin levels in laying, incubating and brooding pheasants (Phasianus colchicus).
Simpson et al. Vervet monkey disease: experimental infection of monkeys with the causative agent, and antibody studies in wild-caught monkeys
Chambers et al. Precipitation of active influenza A virus from extra-embryonic fluids by protamine
GB1010509A (en) Improvements in or relating to newcastle disease virus vaccines
Lawson et al. The ERA strain of rabies vaccine
GB1000907A (en) Attenuated live measles virus vaccine and method of production
KR940010022B1 (en) Live vaccine for contagious diseases of chickens
Hirata et al. Studies on immunologic depression in chickens
US3143470A (en) Rabies virus propagation in embryonic cells maintained in a medium containing pancreatic digest of casein
Fruitstone et al. An interferon produced in response to infection by herpes simplex virus
Beadle et al. Carbon dioxide narcosis
Mitchell et al. Persistence of neutralizing antibody in milk and blood of cows and goats following the instillation of virus into the mammary gland
Cutts et al. Nutrition of a strain of brewer's yeast requiring p-aminobenzoic acid
Faulkner et al. Propagation of a strain of rabbit fibroma virus in tissue-culture
US4004974A (en) Live virus culture vaccine against carnivore distemper and method of producing same
Matsuo et al. Studies on the infectivity of rat virus (RV) in BALB/c mice
Fahey et al. Studies on chronic respiratory disease of chickens VI. The effects of antibiotics on the clinical and serological course of CRD
DE1030516B (en) Nutrient soil for virus breeding
Chung Propagation of Sindbis virus, Murray Valley encephalitis virus and Getah virus
Smith Propagation of rabbit fibroma virus in the embryonated egg.
GB2030451A (en) Anti-clostridium vaccine
Browne Thirst in the Blowfly, Lucilia cuprina
CH380302A (en) Process for the preparation of a combined vaccine for dogs
AT227876B (en)